Charles River Laboratories International (CRL) EPS (Weighted Average and Diluted) (2009 - 2025)

Charles River Laboratories International's EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at -$5.56 for Q4 2025.

• In Q4 2025, EPS (Weighted Average and Diluted) fell 33.33% year-over-year to -$5.56; the TTM figure through Dec 2025 stood at -$2.9 (down 1550.0% YoY), while the FY2025 annual figure was -$2.91, down 1555.0% from the prior year.
• EPS (Weighted Average and Diluted) was -$5.56 for Q4 2025 at Charles River Laboratories International, down from $1.1 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.65 in Q4 2022 to a low of -$5.56 in Q4 2025.
• Historically, EPS (Weighted Average and Diluted) has averaged $1.18 across 5 years, with a median of $1.73 in 2021.
• The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) surged 50.83% in 2022, then tumbled 214.56% in 2024.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.67 in 2021, then soared by 36.7% to $3.65 in 2022, then slipped by 0.27% to $3.64 in 2023, then sank by 214.56% to -$4.17 in 2024, then slumped by 33.33% to -$5.56 in 2025.
• The last three EPS (Weighted Average and Diluted) figures came in at -$5.56 (Q4 2025), $1.1 (Q3 2025), and $1.06 (Q2 2025), per Business Quant data.